Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | RPS6KA2 | Q15349 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12834808 | 0.79 | CYP1A2 (0.50) | CYP1A2ALDH1A1RAB9AKDM4EMAPT | |
| SCHEMBL22649151 | 0.73 | KMT2A (0.45) | CYP1A2ALDH1A1RAB9AKDM4EMAPT | |
| SCHEMBL13134034 | 0.72 | CYP1A2 (0.47) | CYP1A2ALDH1A1RAB9AKDM4EMAPT | |
| SCHEMBL12705657 | 0.72 | CYP1A2 (0.56) | CYP1A2ALDH1A1RAB9AKDM4EMAPT | |
| SCHEMBL14256476 | 0.71 | CYP1A2 (0.50) | CYP1A2ALDH1A1RAB9AKDM4EMAPT | |
| SCHEMBL9184880 | 0.71 | CYP1A2 (0.60) | CYP1A2ALDH1A1RAB9AKDM4EMAPT | |
| SCHEMBL2688179 | 0.69 | ALDH1A1 (0.67) | CYP1A2ALDH1A1RAB9AKDM4EMAPT | |
| SCHEMBL24618177 | 0.68 | CYP1A2 (0.43) | CYP1A2ALDH1A1RAB9AKDM4EMAPT | |
| SCHEMBL4950343 | 0.68 | ASAH1 (0.56) | CYP1A2ALDH1A1DRD3ASAH1 | |
| SCHEMBL5398141 | 0.68 | ALDH1A1 (0.44) | CYP1A2ALDH1A1RAB9AKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050074771-A1 | Carbamate-derivatized nucleosides and oligonucleosides | ISIS PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| US-6803198-B2 | COMPOUND FOR USE IN HUMAN THERAPEUTICS AND DIAGNOSTICS | ISIS PHARMACEUTICALS, INC. | 2004-10-12 | — | — | US | disclosed |
| US-20030039977-A1 | Carbamate-derivatized nucleosides and oligonucleosides | ISIS PHARMACEUTICALS, INC. | 2003-02-27 | — | — | US | disclosed |
| US-6322987-B1 | FOR TREATING AN ANIMAL HAVING A DISEASE CHARACTERIZED BY UNDESIRED PRODUCTION OF PROTEIN | ISIS PHARMACEUTICALS, INC. | 2001-11-27 | — | — | US | disclosed |
| EP-0983291-A4 | CARBAMATE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS INC (US) | 2001-04-04 | — | — | EP | disclosed |
| US-6166188-A | Carbamate-derivatized nucleosides and oligonucleosides | ISIS PHARMACEUTICALS, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| US-6111085-A | COMPOUND HAVING AT LEAST ONE NUCLEOSIDE WITH A DERIVATIVE AT THE 2'-O OR 3'-O POSITION; FOR IMPROVED PROPERTIES AND CONJUGATION OF FUNCTIONAL MOIETIES SUCH AS STEROIDS, REPORTER MOLECULES, REPORTER ENZYMES, LIPOPHILIC MOLECULES | ISIS PHARMACEUTICALS, INC. (US) | 2000-08-29 | — | — | US | disclosed |
| EP-0983291-A1 | CARBAMATE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998011123-A1 | CARBAMATE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1998-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050074771-A1 | Carbamate-derivatized nucleosides and oligonucleosides | RNGTT, NUDT21, DUT | CYP1A2 3034/4885ALDH1A1 3846/4885RAB9A 4667/4885 |
| US-20030039977-A1 | Carbamate-derivatized nucleosides and oligonucleosides | RNGTT, NUDT21, DUT | CYP1A2 3034/4885ALDH1A1 3846/4885RAB9A 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.